
    
      Patients with stage IB2-IIB cervical cancer will be treated with 3 cycles of neoadjuvant
      Carboplatin-Paclitaxel chemotherapy (Carboplatin AUC 5 d1 q 21+ Paclitaxel 175 mg/mq d1 q
      21)+ Pembrolizumab (200 mg flat dose every 3 weeks).

      After 3 cycles of neo-adjuvant platinum-based chemotherapy patients non progressing will
      undergo radical surgery.

      After surgery, patients presenting with high risk factors (positive lymphnodes, positive
      parametria, positive surgical margins or at least 2 of the following risk factor between
      tumor diameter >3 cm, LVSI, stromal infiltration >1/3) will receive 3 cycles of adjuvant
      Carboplatin-Paclitaxel chemotherapy + Pembrolizumab in combination and maintenance with
      Pembrolizumab 200 mg every 3 weeks until progression or unacceptable toxicity or patient
      consent withdrawal for up to 35 cycles.
    
  